Neuronetics (STIM) Expected to Announce Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is projected to post its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Neuronetics to post earnings of ($0.12) per share and revenue of $40.8440 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 8:30 AM ET.

Neuronetics Stock Performance

STIM opened at $1.30 on Friday. The business has a 50 day moving average price of $1.64 and a two-hundred day moving average price of $2.09. The company has a market capitalization of $88.69 million, a price-to-earnings ratio of -1.58 and a beta of 0.87. The company has a debt-to-equity ratio of 2.09, a current ratio of 2.24 and a quick ratio of 2.09. Neuronetics has a 1-year low of $1.17 and a 1-year high of $5.34.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Neuronetics from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

Insider Activity

In related news, CEO Keith J. Sullivan sold 40,976 shares of Neuronetics stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $1.55, for a total value of $63,512.80. Following the completion of the sale, the chief executive officer directly owned 1,567,012 shares in the company, valued at $2,428,868.60. This trade represents a 2.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 104,307 shares of company stock worth $164,097 over the last quarter. Corporate insiders own 8.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Neuronetics by 3.3% during the third quarter. Vanguard Group Inc. now owns 2,832,118 shares of the company’s stock worth $7,732,000 after buying an additional 89,504 shares during the period. UBS Group AG raised its position in Neuronetics by 580.7% in the 3rd quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock valued at $5,910,000 after buying an additional 1,846,801 shares during the last quarter. Lane Generational LLC acquired a new stake in Neuronetics in the 4th quarter valued at approximately $2,353,000. Balyasny Asset Management L.P. lifted its stake in Neuronetics by 6.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,509,099 shares of the company’s stock valued at $5,267,000 after acquiring an additional 92,048 shares in the last quarter. Finally, Wexford Capital LP lifted its stake in Neuronetics by 83.1% in the 3rd quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock valued at $3,214,000 after acquiring an additional 534,155 shares in the last quarter. Institutional investors own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.